Webinar presentations: Update on the Human Lung RNAseq Atlas, Nathan Salomonis, USA; Unsupervised transcriptomic profiling of whole blood shows biologic heterogeneity in iPAH, Allan Lawrie, England; Cellular landscape atlas of pulmonary endarterectomy tissue using single cell RNAseq, Peiran Yang, China; Single cell RNAseq identifies cellular abnormalities in rodent models of PH, Jason Hong, USA.
Webinar presentations: Mechanosensitive cation channels in the pulmonary vascular wall in PAH; Proton exchangers in pulmonary smooth muscle cells in PAH; Pathophysiologic role of mutant potassium channels in pulmonary hypertension; TRPV4 activity in lung microvascular endothelial cells in PAH
Webinar presentations: Clinical challenges in developing drug therapies for children with PH, Challenges related to drug approval for children with PH – regulatory perspective, Challenges facing pharmaceuticals in drug development for paediatric PH, Utility of paediatric registries for the characterization of pulmonary hypertensive phenotypes.
Webinar presentations: Pro-con: All patients should have balloon pulmonary angioplasty before being referred for pulmonary endarterectomy, Hiromi Matsubara (PRO) & Marcin Kurzyna (CON); Pro-con: Pulmonary hypertension recurs after pulmonary endarterectomy in most patients, Irene Lang (PRO) & Timothy Fernandes (CON)
Webinar presentations: Improving accuracy in prognosis in PAH Prognostic Scoring Systems – REVEAL 2.0 onwards, Raymond Benza; Integration of mutational profile into PAH Risk Calculators for better assessment of prognosis, Eric Austin; Integration of biomarkers into PAH Risk Calculators for better assessment of prognosis, Anna Hemnes
Webinar presentations: Genetics of pulmonary arterial hypertension: What we can learn by studying children with and without congenital heart disease, Wendy Chung, Therapeutic options in advanced PVD: Potts shunt versus lung transplantation, Mark Grady, Stem cells and Regenerative Medicine for Neonatal Lung Disease: implications for COPD, Bernard Thebaud, Assessment of operability in patients with congenital heart disease and PAH: Fallacies and pitfalls, Erika B. Rosenzweig, The impact of chronic pulmonary hypertension on ventricular function in extremely premature infants, Gabriela de Carvalho Nunes, Improving guidance for the correctability of congenital cardiovascular shunts with increased pulmonary vascular resistance, Ronald Day
Webinar presentations: Cancer induced PH: Embolism as a major inducer, Timothy Morris, Cancer induced PH: Microenvironmental cancer niche as a major inducer, Rajkumar Savai, Cancer therapies induced PH, Frédéric Perros, Cancer related signalling mechanisms underlying PH development, Olivier Boucherat, FOXO3: A new potential therapeutic target in pulmonary arterial hypertension, Yann Grobs, Non-invasive surrogate markers of PH are associated with poor survival in lung cancer patients, Michael Cekay
Webinar presentations: Age-dependent prevalence of PH in the general population, Harm Jan Bogaard, Senescence mechanisms and pulmonary vascular aging, Serge Adnot, Metabolic Syndrome and obesity leads to age-related PH, Imad Al Ghouleh, Genetics and epigenetics in age-related PH, Stephen Archer, Right heart catheterization is underused in elderly patients suspected of pulmonary hypertension, Samara Jansen
Reversal of PH by whole bone marrow transplantation in BMPR2 deficient mice, James West, Bone marrow dependency of cigarette smoke-induced PH versus emphysema, Norbert Weissmann, Homologous bone marrow transplantation prevents the development of PAH in patients with severe scleroderma, Jason Weatherald, Role of bone marrow in the right ventricle remodelling, Gaurav Choudhary
